

# APONTIS PHARMA

The Single Pill Company



# APONTIS PHARMA Executive Team



**Thomas Milz**

Chief Product Officer

- Business Development
- Market Access
- Medical & Regulatory Affairs
- Product Development



**Karlheinz Gast**

Chief Executive Officer

- Strategy
- Marketing & Sales
- Human Resources
- Investor Relations



**Thomas Zimmermann**

Chief Finance Officer

- Finance
- Supply Chain
- IT
- Compliance



“Drug non-compliance is a stealth epidemic exacting a heavy toll on the healthcare system – our broad portfolio of Single Pills is designed to help tackle this epidemic”



2 · 8 March, 2023

# APONTIS PHARMA

The Single Pill Company




# APONTIS PHARMA VISION

Establish **Single Pill as gold standard**  
For a better life. Together. Every day.



4 · 8 March, 2023



We are passionate about  
maximizing the potential of  
active ingredients through therapy  
simplification and substitution with  
Single Pill.

Mission




5 · 8 March, 2023

# “No More Grandma’s Muesli”

## Single Pill Therapy on the Rise – one pill once daily

### Conventional therapy (loose combinations)



#### Loose Pills

- A** 5 mg / 10 mg
- B** 15 mg / 30 mg
- C** 100 mg

(Available dosages)

Pill 1  
Substance A



Pill 2  
Substance B



Pill 3  
Substance C




**VS.**

**20-50%**  
adherence

### Single Pill therapy



**70-80%**  
adherence



Single\*  
Pill



- 1** 5 mg + 15 mg + 100 mg
- 2** 5 mg + 30 mg + 100 mg
- 3** 10 mg + 15 mg + 100 mg
- 4** 10 mg + 30 mg + 100 mg

Source: START Study, IPAM / INGRESS Institute; Company information  
Available Single Pill dosages



6 · 8 March, 2023

# APONTIS PHARMA with successful growth in 2022

## Financial Highlights FY 2022

### Single Pill Revenues

EURm 36.5

(+16.2%)

### Total Revenues

EURm 55.7

(+8.9%)

### EBITDA

EURm 5.6

(+ EURm 3.2)



Successful FY 2022 in line with our expectations



7 · 8 March, 2023

# Single Pill Achievements 2022





# Achievements 2022


## Patients

- Single Pills of APONTIS PHARMA:
  - 330k patients on year-end
  - Increase of 60k patients vs the previous year
- Strong evidence of Single Pills confirmed by new studies
- Biggest statutory health insurance fund TK (Techniker Krankenkasse), published a positive vote about the value of Single Pills to their patients



9 · 8 March, 2023

# The largest German health insurance recommends Single Pills as the best option to improve therapy adherence



## Less is more: Single Pill Therapy

Mit KHK plus Bluthochdruck steigt die Zahl der verordneten Medikamente.  
... For this reason, Single Pill therapy is even recommended as standard therapy in international guidelines...

... this form of therapy increases adherence by an average of c.30%... so **less is more**... but dreaded complications of high blood pressure, such as heart attack or heart failure, also decreased.

**Therefore, ask whether your high blood pressure medications can be prescribed as a Single Pill.**



# Achievements 2022

## Customers

- Substantial increase in acceptance of the additional value of Single Pill vs loose combinations
- The number of digital patient identifications for our Single Pills increased by 59% to 4,240
- Results of the substitution adoption ladder in the second half of 2022 are promising

Adoption	Stage 0	Stage 1	Stage 2	Stage 3	Stage 4	Stage 5
Physicians	545	3,077	7,694	5,453	478	86
	3.14%	17.75%	44.39%	31.46%	2.76%	0.50%



# Achievements 2022


## Employees

- **Launch of Long-Term Retention Programs**
  - Stock program for all employees with a three-year duration
  - Stock program with 1,500 shares for newcomers in the sales force with a five-year duration
- **Excellent Commitment of Employees to the Strategy of APONTIS PHARMA and Single Pill treatment concept**



# High Commitment of Employees to APONTIS PHARMA's Strategy

## Employee Survey APONTIS PHARMA ECHO with outstanding results



Nur für den internen Gebrauch.



13 · 8 March, 2023


# Achievements 2022

## ESG activities

- E** First evaluation of the environmental footprint of Single Pills vs loose combinations
- S** Stock program for employees to participate in company success
- G** Launch of Code of Conduct, Anti-Bribery/Anti-Corruption policy and Whistleblower Hotline



# Single Pill have a strong CO<sub>2</sub> advantage in comparison to loose combinations



Source: Ernst & Young

All data refer to daily dosis per tablet/pill.



15 · 8 March, 2023

# Single Pill's Clinical Evidence





# The Single Pill – Clinical Evidence retrospective and prospective study results were published first time ever



## Metaanalysis:

- Better adherence and persistence to medication with Single Pills



## START 1.0

- Single Pills improve persistence and clinical outcomes



## START 2.0

- The Single Pill as a concept improves persistence and clinical outcomes

New



## SECURE

- The Single Pill improves persistence and clinical outcomes in an RCT

New



## NEPTUNO

- The Single Pill improves persistence, clinical outcomes, blood pressure- and LDL-cholesterol- control

New



# Single Pills' High Effectiveness and Increased Health Benefits Confirmed

Full  
publication  
released




- ~2,499 participants
- Primary objective:** Evaluation of the efficacy of a Single Pill in secondary prevention
- Single Pill vs usual care\* (1:1 randomization)
- Follow-up: 2-4 years
- Primary Endpoint: MACE (CV-Death, non-fatal MI, non-fatal stroke, urgent revascularization)

### Key findings:


- ✓ Greater adherence to therapy
- ✓ 24% risk reduction in MACE
- ✓ 33% risk reduction in CV-Death

## Therapy Adherence Driven by Single Pills Is Proven to lead to Significant Health Benefits for Patients

### Adherence to therapy in %



### Risk Reduction by Single Pill in %<sup>1</sup>



Notes: (1) Defined Endpoint: MACE = death from cardiovascular causes, non-fatal myocardial infarction, non-fatal ischaemic stroke or urgent revascularization


\* Usual care according to the local clinical practices at each participating country

Source: Castellano JM et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Aug 26. doi: 10.1056/NEJMoa2208275.



# Superiority of Single Pills in SECURE Study, Secondary Cardiovascular Prevention

## Result of secondary outcome\*



- Advantages evident at an early stage<sup>1)</sup>
- Advantages evident increase over the course of treatment<sup>2)</sup>

\*cardiovascular-related death, nonfatal myocardial infarction, non-fatal stroke

Source: Castellano, JM et al. "Polypill Strategy in Secondary Cardiovascular Prevention." The New England journal of medicine, 10.1056/NEJMoa2208275.




# Single Pill Pipeline



# APONTIS PHARMA with successful year 2022

## New Single Pill launches and pipeline progress




Further expansion of our Single Pill portfolio



21 · 8 March, 2023

# Short-term Pipeline:

## Accelerating the Development of Single Pills, 2023 (n = 3)

Field of application 	AP – D 12	AP – D 13	Rosazimib (AP – D 01)
Planned market launch	Mid 2023	Mid 2023	June 2023
Status	Dossier submitted	Already approved	Dossier submitted
Competitive environment	Two other Single Pill providers with this combination	One other Single Pill provider with this combination	Six other Single Pill providers with this combination already on the market
Min. patient potential <sup>2</sup>	900 k	110 k	85 k
Total development cost	EURm 1.0 (Triple-Exclusive license agreement)	EUR 250,000 (Semi-Exclusive license agreement)	EURm 0.0 (Exclusive license agreement)
Mid-term annual revenue potential	EURm 5 - 7	EURm 1.3	EURm 3

Licensed-in  
own development


Notes: (1) Main application essential hypertension; (2) Patient potential: number of patients with the same substance class combination in loose form  
Source: Patient INSIGHTS Analytics (PIA). A web-based pharmaceutical tool from INSIGHT Health GmbH & Co. KG; Company Information



22 · 8 March, 2023

# Short-term Pipeline:

## Accelerating the Development of Single Pills, 2024 (n = 4)

Field of application 	<b>Caramlo HCT</b> (AP - T 01)	AP - D 04	AP - D 02	<b>Caramlo Ator</b> (AP - T 02)
Planned market launch	Q1 2024	Q3 2024	Q4 2024	Q4 2024
Status	Dossier submitted in March 2022	Dossier development ongoing	Dossier development ongoing	Dossier submitted in September 2022
Competitive environment	One other Single Pill provider with this combination	No other Single Pill provider with this combination	No other Single Pill provider with this combination	No other Single Pill provider with this combination
Min. patient potential <sup>2</sup>	150 k	12 k (Exclusive license agreement)	7 k (Exclusive license agreement)	120 k
Total development cost	EURm 1.3	none	none	EURm 2.5
Mid-term annual revenue potential	EURm 6 - 8	EURm 2 - 3	EURm 1.8	EURm 6

Licensed-in  
own development

Notes: (1) Main application essential hypertension; (2) Patient potential: number of patients with the same substance class combination in loose form  
Source: Patient INSIGHTS Analytics (PIA). A web-based pharmaceutical tool from INSIGHT Health GmbH & Co. KG; Company Information



23 · 8 March, 2023

# Mid-term Development Pipeline: Continuous Market Opportunities

Development candidates (n = 15)

(Exclusive) In-Licensing agreements (n = 18)

Code/Produkt	Vertragsart	Projekt Status	Revenue Potential (Peak Sales in EURm)
AP - D 05	Auftragsentwicklung EU	4 - in development	9.4
AP - D 06	Auftragsentwicklung EU	4 - in development	10.5
AP - D 07	Auftragsentwicklung EU	4 - in development	5.8-0
AP - D 09	Auftragsentwicklung EU	2 - in advanced negotiation	7.7
AP - D 10	Auftragsentwicklung EU	2 - in advanced negotiation	7.7
AP - T 01 (Caramio HCT)	Auftragsentwicklung EU	2 - MAA submitted	5.8-9.2
AP - T 02 (Caramio Lipid)	Auftragsentwicklung DE	5 - MAA submitted	6.0
AP - T 03	Auftragsentwicklung EU	4 - in development	11.6
AP - T 04	Auftragsentwicklung EU	2 - in advanced negotiation	5.0-6.0
AP - T 05	Auftragsentwicklung EU	2 - in advanced negotiation	5.0-6.0
AP - T 06	Auftragsentwicklung EU	1 - in negotiation/planned	5.0-6.0
AP - T 09	Auftragsentwicklung EU	2 - in advanced negotiation	4.5-5.5
AP - T 12	Auftragsentwicklung EU	2 - in advanced negotiation	5.0-6.0
AP - T 13	Auftragsentwicklung EU	2 - in advanced negotiation	not defined yet
AP - T 14	Auftragsentwicklung EU	2 - in advanced negotiation	not defined yet

Code/Produkt	Vertragsart	Projekt Status	Revenue Potential (Peak Sales in EURm)
AP - D 01 (Rosazimb)	Lizenzierung	8 - MAA submitted	3.0
AP - D 02	Lizenzierung	3 - signed contract	1.8
AP - D 03	Lizenzierung	3 - signed contract	21.0
AP - D 04	Lizenzierung	3 - signed contract	2.6
AP - D 08	Lizenzierung	1 - in negotiation/planned	7.6
AP - D 11	Lizenzierung	2 - in advanced negotiation	8.0-10.0
AP - D 12	Lizenzierung	2 - in advanced negotiation	5.0-7.0
AP - D 13	Lizenzierung	3 - signed contract	1.3
AP - D 14	Lizenzierung	2 - in advanced negotiation	4.0+11.4+18.5
AP - D 16	Lizenzierung	1 - in negotiation/planned	4.4
AP - D 17	Lizenzierung	1 - in negotiation/planned	5.6
AP - D 18	Lizenzierung	2 - in advanced negotiation	1.8
AP - T 07	Lizenzierung	2 - in advanced negotiation	2.5-3.5
AP - T 08	Lizenzierung	2 - in advanced negotiation	7.5-8.5
AP - T 10	Lizenzierung	2 - in advanced negotiation	2.4
AP - T 11	Lizenzierung	1 - in negotiation/planned	3.0-4.0 (TM assigned)
AP - D 15	Lizenzierung	2 - in advanced negotiation	2.0
AP - D 19	Lizenzierung	2 - in advanced negotiation	not defined yet

**33 new Single Pills in the Pipeline**

- 3 in registration
- 4 under own development
- 5 In-Licensing agreements
- 4 in advanced negotiation
- 17 in discussion

Source: Patient INSIGHTS Analytics (PIA). A web-based pharma tool from INSIGHT Health GmbH & Co. KG; Company information


Note: AP = APONTIS PHARMA | D = Double combination / T = Triple combination





# APONTIS PHARMA: The Single Pill Strategy

## Repeating Success




APONTIS expertise and market access meet the demand for Single Pill development of commonly prescribed drugs available only as loose combinations



25 · 8 March, 2023

# APONTIS PHARMA with successful year 2022

Cooperation business prolonged and increasing focus by divestiture



# FINANCIALS FY 2022



# APONTIS PHARMA with successful growth in 2022

## Financial Highlights FY 2022

### Single Pill Revenues

EURm 36.5

(+16.2%)

### Total Revenues

EURm 55.7

(+8.9%)

### EBITDA

EURm 5.6

(+ EURm 3.2)



Successful FY 2022 in line with our expectations

Note: Rounding differences may occur. Source: Company data; unaudited financials.




28 · 8 March, 2023

# Momentum for Single Pills continues

## Revenues FY 2022

(in EURm)



### **Growth in Single Pills driven in particular by Atorimib, Tonotec, Tonotec HCT and Biramlo**

- 6 out of 7 Single Pills with double-digit growth.
- Three new Single Pills launched.
- Caramlo below prior year due to tender and high wholesaler stockpiling in December 2021 (EURk 500).

### **Fee-per-call share is now at 22% of total cooperation business, up from 10% in 2021**

- Ulunar sales declined by 9% (EURm 0.7), lower than expected.
- Jalra/Icandra - 21% (EURm 1.6) as a Co-Marketing contract with Novartis expired end of September 2022.
- Trixeo fee for call grew with a rate of 69%.

### **Others**


- Normal cough season after the end of COVID restrictions (Codicaps®). Better Magno Sanol® sales.
- Gynaecology business divested in March 2022.



# Single Pill and fee-per-call business drive EBITDA development

## Change in Ulunar contract and expiration of Jalra/Icandra covered




EBITDA development 2022



# APONTIS PHARMA: Dynamic continuation of growth course

## Key performance indicators FY 2022

(in EURm)



### Revenues




- Single Pills +16.2%
- Cooperation -1.9%
- Others - 8% (influenced by the divestment of the Gyn products)

### Gross Profit

- Decline in gross profit margin impacted by Ulunar (Novartis): contract changed from Co-marketing to distribution model (EURm 2.1). Changed treatment of post-milestone payments in 2022 (impact EURm 0.9).  
**=> adjusted pro-forma margin would have increased by 180bps**

Note: Rounding differences may occur.  
Source: Company data; unaudited financials

### EBITDA/Net Result



- Higher sales compared to the previous period and IPO costs of EURm 3.5 in 2021 main drivers of profitability increase.
- Further investment in marketing and salesforce (+8 FTE on average)
- Gross profit impact related to changed Co-Marketing contract
- Income from the divestment of Gyn products in the amount of approx. EUR 0.6 Mio.
- Repayment of shareholder loan in 2021: EUR 0.4 Mio lower interest expense.



# Solid Financial Position: Well-Funded for Planned Activities

in EURk	Dec 22		Δ
	ACT	Dec 21	
<b>Total equity and capitalization difference</b>	<b>42 271</b>	<b>41 413</b>	<b>858</b>
A. Total working capital	- 7 145	- 1 290	- 5 854
I. Trade net working capital	723	5 177	- 4 454
1. Inventories	3 164	4 598	- 1 433
2. Receivables and other assets	2 918	3 581	- 664
3. Accounts payables	- 5 359	- 3 002	- 2 357
II. Prepaid expenses	435	443	- 9
III. Other liabilities	- 734	- 724	- 10
IV. Other accruals	- 7 568	- 6 186	- 1 382
B. Long-term assets	16 193	14 886	1 306
I. Intangible fixed assets	16 148	14 691	1 457
II. Tangible fixed assets	45	19	26
III. Deferred tax assets		176	- 176
C. Net cash	33 223	27 817	5 406
I. Pension accruals	- 2 686	- 2 423	- 264
II. Financial assets	799	784	15
III. Tax accruals	- 1 235	- 384	- 851
IV. Cash	36 345	29 840	6 505

Note: Rounding differences may occur.

Source: Company data; unaudited financials

- Total working capital negative.
- Inventories mainly lower due to supply issues. Supplies were shipped directly to wholesalers in order to meet demand.
- Receivables lower as we shifted SEPA direct debit in December 2021 by one month to avoid negative interest rates.
- Increase in fixed assets driven by further milestone payments for development projects.
- Increase net cash driven by profit and lower working capital.
- Equity increased due to profit. Purchase of own shares (EURm 1.8) and higher total assets causes a lower equity ratio of 69.4%.





# Strong cash generation in 2022

## Based on profit development and lower working capital

in EURk	Dec 22	Dec 21	Δ	Growth
	ACT			
<b>Cash BoP</b>	<b>29 840</b>	<b>8 059</b>	<b>21 781</b>	<b>270%</b>
<b>Operating flow</b>	<b>11 020</b>	<b>3 433</b>	<b>7 586</b>	<b>221%</b>
Net profit	2 689	- 745	3 434	361%
Depreciation & amortization	1 795	1 746	49	3%
Accruals	1 598	1 449	149	10%
Inventories & receivables	2 109	- 3 318	5 427	64%
Payables	2 367	- 624	2 991	379%
Taxes	847	503	344	68%
Interests	- 16	401	- 417	-104%
Other	- 369	4 022	- 4 391	-109%
<b>Investing flow</b>	<b>- 2 679</b>	<b>- 1 773</b>	<b>- 906</b>	<b>51%</b>
<b>Financing flow</b>	<b>- 1 836</b>	<b>20 121</b>	<b>- 21 957</b>	<b>-109%</b>
<b>Cash EoP</b>	<b>36 345</b>	<b>29 840</b>	<b>6 505</b>	<b>22%</b>
<b>Change in cash and cash equivalents</b>	<b>6 505</b>	<b>21 781</b>	<b>- 15 277</b>	<b>-70%</b>

- Higher net profit and lower working capital have increased operating cash flow.
- Lower Working Capital driven by lower supplies and higher payables. SEPA direct debits for receivables shifted by one month in December 2022.
- Investing cash flow for milestone payments.
- Financing cash flow represents the buy-back of shares.

Note: Rounding differences may occur.

Source: Company data; unaudited financials



# Outlook 2023



# Single Pill – Outlook 2023

## Pipeline/Scientific Approach

### Pipeline:

- New contracts for In-licensing and own developments in place

### Scientific:

- New trials to support the benefit of Single Pills have already been planned and started
- New congresses will be used to present the advantages of Single Pill treatment

## Commercial

### Expansion of Marketing and Sales activities

- Increasing number of scientific events to secondary prevention with Single Pills driven by SECURE trial
- Additional digital activities for patient identification
- Expansion of hospital activities
- Expansion of activities to payers driven by robust scientific package



Strong development of scientific evidence in 2022 is a good basis for further growth



# Requirement for Behavior Change in Long-term Treatment

Physicians are aware and convinced about outstanding benefits of Single Pills vs loose combinations.

Excellent and reliable sales force:

- to educate physicians about the value of Single Pill
- to support patient identification with a loose combination

Digital activities to simplify patient identification for respective Single Pills

- APONTIS PHARMA is working on additional digital solutions



APONTIS PHARMA is well-positioned for Single Pill business



# Digital Activities

Identification of respective Single Pills from the Medication Plan by

- Smart Phone and
- PC-Screenshot




# Example of a patient's Medication Plan

Medication Plan							
ingredients	dosage	strength	presentation				
Ezetimib	Ezetimib 10mg Tabletten	10mg	TAB	1	0	0	0
Amlodipin	Amlodipin 5mg Tabletten	5mg	TAB	1	0	0	0
Pantoprazol	Pantoprazol 20mg magensaftres. Tab.	20mg	TAB	1	0	0	0
Ramipril	Ramipril 10mg Tabletten	10mg	TAB	1	0	0	0
Atorvastatin	Atorvastatin 20mg Tabletten	20mg	FTA	1	0	0	0
Metformin	Metformin 850 mgTabletten	500 mg	FTA	1	0	1	1
ASS	ASS 100 100mg Tabletten	100 mg	TAB	1	0	0	0
Venlafaxin	Venlafaxin 37,5 mg Kapseln	37,5 mg	REK	1	0	1	0
Hydrochlorothiazid	Hydrochlorothiazid 100mg Tabletten	25mg	TAB	1	0	0	0
Allopurinol	Allopurinol 100 mgTabletten	100mg	Tab	1	0	0	1
Bisoprolol	Bisoprolol 5mg Tabletten	5mg	FTA	1	0	0	0



# Double tailwind from the target group market


## Aging Society (Germany)



### Increasing age leads to high prevalence of hypertension

- Population > 65 with strong growth driven by the baby boomer generation
- Increasing number of older people speeds up Single Pills demand
- APONTIS PHARMA to capitalise demand with growing Single Pill-Portfolio

## Rise of Chronic Diseases (Germany)



### Hypertension – Aging society-driven epidemic

- CVD is the leading cause of death in Germany
- A large untapped market
- APONTIS PHARMA focuses on Single Pills



Two factors driving demand for Single Pills: Increasing age and associated trend in morbidity


Source: German Federal Ministry for Economic Affairs and Energy, Robert Koch-Institute 2015, Study DEGS1, Period under investigation 2008-2011



# Additional tailwind:

## Growth of all substance classes in hypertension treatment


### Aging Society (Germany)



### Hypertension – Aging society-driven epidemic

- CVD is the leading cause of death in Germany
- A large untapped market
- APONTIS PHARMA focuses on Single Pills

### Demand for Monosubstances (Germany)



### Established ingredients strong growth driven by aging society

- Over 20 million patient-years growth in the past decade
- Aging society (baby boomers) accelerates growth
- Single Pill potential free from new therapeutics competition for at least 10 years



Single Pills: Portfolio growth of established and new Single Pills free from therapeutics competition


Source: German Federal Ministry for Economic Affairs and Energy, Robert Koch-Institute 2015, Study DEGS1, Period under investigation 2008-2011



# Strong Pipeline and Patients Potential drive growth Expectations


## Single Pill portfolio – Development

(number of Single Pills)



## Patient potential of Single Pill – Portfolio

(in million patients)






# Single Pill concept is a Scalable Business Model

- **Growing share of physicians becoming familiar with Single Pills driven by strong clinical evidence and high patient acceptance**
- Need for **educational effort** will **diminish** over time as **evidence** can be transferred to new **Single Pills**
- **Pharmaceutical ingredients well-known and widely-used in daily practice**
- **Patients already on respective loose combinations only need to be substituted with respective Single Pill** by physicians
- **Substitution of loose combinations by Single Pills to be a standard process** in daily practice supported by **digital activities** to **identify the appropriate patients**
- Current **target group** fits all expected **Single Pill launches** with **no need for additional sales force**




Marketing and sales costs as a share of net sales are expected to go down from >40% in 2021 to <25% in medium-term




# FY23 is a year of transition: Increase in Single Pills cover partially the expiration of the Jalra/Icandra Co-Marketing contract


## Group Revenues (in EURm)



## Group EBITDA (in EURm)




## Mid-term Targets



Notes: \* EBITDA 2021 adjusted by IPO costs is EURm 5.9 and adjusted margin at 11.5%  
 Group figures for FY22 are unaudited and preliminary. Rounding differences may occur.  
 Source: Company information, unaudited financials

42 · 8 March, 2023

YOUR  
QUESTIONS  
PLEASE!



**THANK YOU**  
**FOR YOUR ATTENTION!**

ir@apontis-pharma.de  
T: +49 2173 89 55 4900  
F: +49 2173 89 55 1521

Alfred-Nobel-Str. 10  
40789 Monheim am Rhein  
Deutschland

apontis-pharma.de



# Single Pills' High Effectiveness and Increased Health Benefits Confirmed

Full publication released

Neptuno


- ~6,500 participants
- Single Pill, mono components, equipotent mono components, and other therapies
- Anonymized medical history dataset covering patients contained in the BIG-PAC® administrative database
- Data on adherence collected over two year

### Key findings:


- ✓ Greater adherence to therapy
- ✓ Better BP and LDL-Cholesterol-control
- ✓ Better prognosis for patients

## Therapy Adherence Driven by Single Pills Is Proven to lead to Significant Health Benefits for Patients

### Adherence to therapy in %



### Major Cardiovascular Events (MACE) in %<sup>1</sup>



Notes: (1) Defined Endpoint: MACE = death from cardiovascular causes, myocardial infarction, angina, ischaemic stroke, transient ischaemic attack or peripheral artery disease BP = Blood Pressure; LDL = Low Density Lipoprotein.

Source: Gonzalez-Juanatey JR et al., International Journal of Cardiology. 2022; 361: 116-123

